STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc. (STTK) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D+ (1.7) | C- (2.1) | C (2.5) | C+ (2.6) | C (2.3) |
| 2026-11-08 | F (0.6) | D+ (1.6) | C- (2.1) | C (2.4) | C+ (2.6) | D+ (1.8) |
| 2026-11-01 | F (0.3) | D+ (1.6) | C- (2.1) | C+ (2.6) | C+ (2.7) | D+ (1.8) |
| 2026-10-25 | F (0.3) | D+ (1.6) | C- (2.1) | C (2.3) | C+ (2.6) | D+ (1.8) |
| 2026-10-18 | F (0.4) | D+ (1.6) | C- (2.1) | C (2.2) | C+ (2.6) | D+ (1.8) |